ELDN stock gains as FDA clears clinical trial for kidney disease candidate (NASDAQ:ELDN) | Seeking Alpha

2022-09-10 00:14:38 By : Mr. frankie zhang

Grandbrothers/iStock Editorial via Getty Images

Grandbrothers/iStock Editorial via Getty Images

Early August, ELDN announced that the FDA greenlighted a mid-stage trial for tegoprubart as a treatment to prevent organ rejection in patients who underwent a kidney transplant.